Ruben A. Mesa, MD, FACP
Professor and Chair, Division of Hematology and Medical Oncology Deputy Director, Mayo Clinic Cancer Center, Professor of Medicine, Scottsdale, ArizonaAuthored Items
Andrew Bai, MS, Ruben A. Mesa, MD, FACP, Dilan Paranagama, PhD, Shreekant Parasuraman, BPharm, PhD, Jingbo Yu, PhD
November 2017 Vol 8, No 11
The MPNs myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are associated with a variety of burdensome symptoms (BMC Cancer. 2016;16:167) and reduced survival compared with the general population (PLOS One. 2014;9:e90299).
Supplement October 2014 Vol 5, No 5
In an effort to crystallize the evolving and practical application of diagnostic algorithms, prognostication, therapeutic goal setting, and disease management, a multidisciplinary roundtable was convened, which was comprised of physicians from MPN-focused academic centers, community hematologists, outpatient nursing staff, insurance plan administrators, and specialty pharmacists.
Last modified: June 5, 2018